Drug
Bgb A445
Bgb A445: highest development phase Phase 2, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB-A445 NCT05635708 | Phase 2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Bgb A445 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.